At present, research on SPARCL1 has mainly been performed in the context of cancers, including lung cancer [67, 68], prostate cancer [69], colon cancer [70], etc. Little is known about its function in the context of cardiovascular disease. This evidence concerns the gene SPARCL1 and prostate cancer.